Stock 301263 GUANGDONG TAIENKANG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Guangdong Taienkang Pharmaceutical Co., Ltd.

Equities

301263

CNE1000058X0

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-07-04 pm EDT 		5-day change 1st Jan Change
12.47 CNY +2.63% Intraday chart for Guangdong Taienkang Pharmaceutical Co., Ltd. -0.48% -23.64%
May. 14 Guangdong Taienkang Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023 CI
Apr. 22 Guangdong Taienkang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GUANGDONG TAIENKANG PHARMACEUTICAL CO., LTD. Stock Guangdong Taienkang Pharmaceutical Co., Ltd.
-23.64% 727M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.89% 823B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.52% 627B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.55% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.99% 320B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.92% 295B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.74% 239B
B+
NOVARTIS AG Stock Novartis AG
+13.83% 220B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-0.49% 219B
A+
AMGEN INC. Stock Amgen Inc.
+7.94% 167B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
-
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 301263 Stock
  4. Ratings Guangdong Taienkang Pharmaceutical Co., Ltd.